logoOmicsDI
  • Browse
  • Submit Data
  • Databases
  • API

1 Result

Show all   Save search   Copy query

Show results for

  • UnknownUnknown (1)

Publication Date

Release Date

  • Previous page
  • 1 / 1
  • You're on page 1
  • Next page
Sort   by:  
Relevance
 Page size 
10
UnknownReply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welen, Ebba Rosendal, Magnus Gisslen, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients.
Not available
S-EPMC8864103 | biostudies-literature
  • Previous page
  • 1 / 1
  • You're on page 1
  • Next page
Sort   by:  
Relevance
 Page size 
10
OmicsDI is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

EMBL-EBI logoEMBL-EBI logo

OmicsDI Databases

  • PRIDE
  • PeptideAtlas
  • MassIVE
  • JPOST Repository
  • Physiome Model Repository
  • EGA
  • EVA
  • ENA
  • LINCS
  • PAXDB
  • Cell Collective
  • MetaboLights
  • Metabolomics Workbench
  • MetabolomeExpress
  • GNPS
  • BioModels
  • FAIRDOMHub
  • ArrayExpress
  • dbGaP
  • ExpressionAtlas
  • GEO
  • NODE

Information

  • Databases
  • Help
  • API
  • Contact us
  • Code on GitHub
  • Terms of use
  • Submit Data